Stocks · News reference

RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target

Sep 22, 2026, 1:24 PMBenzinga Newsdesk

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 25, 2026, 6:53 PMBenzinga News-desk
FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
INCY MIRM
BenzingaSep 22, 2026, 12:36 PMBenzinga Newsdesk
Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3
Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October
INCY
BenzingaSep 22, 2026, 12:01 PMAvi Kapoor
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
ALIT DGX ERIC GDLC INCY